Colep, Moberg Pharma deal

The companies partnered to develop Moberg’s MOB-015 to treat onychomycosis. Colep will be responsible for scale-up of manufacturing processes, stability programs and supplying clinical trial material for the Phase III program. Colep will also provide documentation needed for regulatory applications in the U.S. and EU. ...